Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oculis Holding AG (OCS)
USD12.86
-0.07 (-0.54%)
CH NASDAQ Healthcare Biotechnology
Address
Bahnhofstrasse 7 6300
Zug, CH
Zug, CH
CEO
Riad Sherif
Website
oculis.com
IPO
2021-05-18
CIK 1953530 ISIN CH1242303498
Description
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.86
-0.07 (-0.54%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
707.0K
Beta
0.20
Float Shares
36.26M
Free Float %
63.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.16% | +1.13% | +15.67% | +10.11% | +62.62% | +57.09% | +76.63% | +183.63% | +223.40% | +223.40% | +223.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
12.86
Low
47.00
+265.5%
Consensus
48.50
+277.1%
Median
48.50
+277.1%
High
50.00
+288.8%
DCF (Unlevered)
1.92
-85.0%
DCF (Levered)
1.94
-84.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
50.00
+288.8%
|
| Last Year | 5 |
42.00
+226.6%
|
| All Time | 7 |
39.57
+207.7%
|
Quality scores
Altman Z-Score
14.62
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+14.6% Q1'26: +27.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +387.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+29.6% Q1'26: +22.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 8 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 801.8K (-100.0%)
|
—
est: 783.6K (-100.0%)
|
686.0K
est: 903.4K (-24.1%)
|
—
est: 794.3K (-100.0%)
|
5.43M
398.5K – 20.31M
+583.4% YoY
|
34.05M
7.05M – 57.52M
+527.3% YoY
|
122.93M
10.18M – 384.37M
+261.0% YoY
|
341.80M
28.30M – 1.07B
+178.0% YoY
|
667.80M
55.28M – 2.09B
+95.4% YoY
|
| EBITDA |
-31.90M
est: 481.1K (-6,731.2%)
|
-87.09M
est: 470.2K (-18,624.5%)
|
-72.80M
est: 542.0K (-13,530.4%)
|
-79.15M
est: 476.6K (-16,707.5%)
|
3.26M
239.1K – 12.19M
+583.4% YoY
|
20.43M
4.23M – 34.51M
+527.3% YoY
|
73.76M
6.11M – 230.62M
+261.0% YoY
|
205.08M
16.98M – 641.23M
+178.0% YoY
|
400.68M
33.17M – 1.25B
+95.4% YoY
|
| EBIT |
-32.20M
est: 481.1K (-6,793.4%)
|
-87.38M
est: 470.2K (-18,685.5%)
|
-73.20M
est: 542.0K (-13,605.3%)
|
-79.15M
est: 476.6K (-16,707.5%)
|
3.26M
239.1K – 12.19M
+583.4% YoY
|
20.43M
4.23M – 34.51M
+527.3% YoY
|
73.76M
6.11M – 230.62M
+261.0% YoY
|
205.08M
16.98M – 641.23M
+178.0% YoY
|
400.68M
33.17M – 1.25B
+95.4% YoY
|
| Net Income |
-38.70M
est: -69.90M (+44.6%)
|
-88.80M
est: -60.13M (-47.7%)
|
-85.78M
est: -85.85M (+0.1%)
|
-94.51M
est: -78.49M (-20.4%)
|
-96.98M
-111.70M – -82.26M
-23.6% YoY
|
-100.94M
-120.81M – -61.78M
-4.1% YoY
|
-36.18M
-836.21M – 1.36B
+64.2% YoY
|
44.30M
-8.52M – 166.78M
+222.5% YoY
|
151.03M
-29.06M – 568.59M
+240.9% YoY
|
| SGA |
6.74M
est: 5.74M (+17.5%)
|
14.72M
est: 5.61M (+162.5%)
|
21.81M
est: 6.47M (+237.2%)
|
24.63M
est: 5.69M (+333.2%)
|
38.85M
2.85M – 145.38M
+583.4% YoY
|
243.73M
50.45M – 411.71M
+527.3% YoY
|
879.91M
72.84M – 2.75B
+261.0% YoY
|
2.45B
202.54M – 7.65B
+178.0% YoY
|
4.78B
395.71M – 14.95B
+95.4% YoY
|
| EPS |
-1.18
est: -5.40 (+78.1%)
|
-2.97
est: -1.60 (-85.4%)
|
-2.12
est: -1.85 (-14.4%)
|
-1.81
est: -1.77 (-2.4%)
|
-1.79
-2.13 – -1.57
-1.5% YoY
|
-1.80
-2.31 – -1.18
-0.5% YoY
|
-1.10
-15.97 – 25.98
+39.0% YoY
|
0.85
-0.16 – 3.19
+176.9% YoY
|
2.88
-0.55 – 10.86
+240.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-20 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-69.66M
OE per share TTM
-1.34
Owner's Yield
-3.81%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,397.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
124.06M
Insider transactions (90d)
0
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LSP 7 Coöperatieve U.A. | 5.33M | 14.60% | — | 5.33M | — | 5.33M | OO | — | 2024-02-09 | ↗ |
| 2 | LSP 7 Management B.V. | 5.33M | 14.60% | — | 5.33M | — | 5.33M | OO | — | 2024-02-09 | ↗ |
| 3 | Brunnur vaxtarsjóður slhf | 2.34M | 7.10% | 2.34M | — | 2.34M | — | OO | Iceland | 2023-05-04 | ↗ |
| 4 | Novartis AG | 2.18M | 6.70% | — | 2.18M | — | — | HC, CO | Switzerland | 2023-03-13 | ↗ |
| 5 | NF Investment Holdings Limited | 2.17M | 5.20% | — | 2.17M | — | 2.17M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 6 | Nan Fung Group Holdings Limited | 2.17M | 5.20% | — | 2.17M | — | 2.17M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 7 | Nan Fung Life Sciences Holdings Limited | 2.17M | 5.20% | — | 2.17M | — | 2.17M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 8 | BEYEOTECH | 2.07M | 6.23% | — | 2.07M | — | 2.07M | CO | Peoples Republic China | 2023-05-02 | ↗ |
| 9 | BVCF IV GP, Ltd. | 2.07M | 6.23% | — | 2.07M | — | 2.07M | PN | Peoples Republic China | 2023-05-02 | ↗ |
| 10 | BVCF IV, L.P. | 2.07M | 6.23% | — | 2.07M | — | 2.07M | PN | Peoples Republic China | 2023-05-02 | ↗ |
| 11 | Zhi Yang | 2.07M | 6.23% | — | 2.07M | — | 2.07M | IN | Peoples Republic China | 2023-05-02 | ↗ |
| 12 | Novartis Bioventures Ltd. | 1.78M | 5.40% | — | 1.78M | — | — | CO | Switzerland | 2023-03-13 | ↗ |
| 13 | Pivotal Life Sciences Holdings Limited | 1.74M | 4.20% | — | 1.74M | — | 1.74M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 14 | Pivotal Partners Ltd | 1.74M | 4.20% | — | 1.74M | — | 1.74M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 15 | Pivotal bioVenture Partners Fund I G.P., L.P. | 1.74M | 4.20% | — | 1.74M | — | 1.74M | PN | British Virgin Islands | 2024-12-09 | ↗ |
| 16 | Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 1.74M | 4.20% | — | 1.74M | — | 1.74M | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 17 | Pivotal bioVenture Partners Fund I, L.P. | 1.74M | 4.20% | — | 1.74M | — | 1.74M | PN | British Virgin Islands | 2024-12-09 | ↗ |
| 18 | NFLS Beta Limited | 436.4K | 1.00% | — | 436.4K | — | 436.4K | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 19 | NFLS Platform Holdings Limited | 436.4K | 1.00% | — | 436.4K | — | 436.4K | CO | British Virgin Islands | 2024-12-09 | ↗ |
| 20 | Novartis Pharma AG | 401.7K | 1.20% | — | 401.7K | — | — | CO | Delaware | 2023-03-13 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-31 vs prev Q
New positions
2
Closed positions
33
Increased
4
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 149.8K +149.8K (+100.0%) | 2.99B +3.0B (+100.0%) | 0.28% +0.284 pp | 1.75% +1.754 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 2 | EQT FUND MANAGEMENT S.A R.L. | 5.90M +— (+0.0%) | 117.83M +14.1M (+13.6%) | 11.20% +0.000 pp | 10.60% +5.029 pp | USD17.58 +13.6% | 2 qtrs — |
| 3 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 2.29M -12.1K (-0.5%) | 45.70M +5.3M (+13.0%) | 4.35% -0.023 pp | 17.67% -5.713 pp | USD10.86 +83.9% | 12 qtrs — |
| 4 | ABRDN PLC | 1.75M +493.8K (+39.4%) | 34.89M +12.7M (+57.0%) | 3.32% +0.938 pp | 0.05% +0.019 pp | USD15.41 +29.6% | 9 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 1.36M +1.4M (+100.0%) | 27.08M +27.1M (+100.0%) | 2.57% +2.575 pp | 0.00% +0.005 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 6 | SR ONE CAPITAL MANAGEMENT, LP | 641.0K +318.5K (+98.8%) | 12.80M +7.1M (+125.8%) | 1.22% +0.605 pp | 1.81% +0.992 pp | USD19.50 +2.4% | 4 qtrs — |
| 7 | SATURN V CAPITAL MANAGEMENT LLC | 516.8K +516.8K (+100.0%) | 10.32M +10.3M (+100.0%) | 0.98% +0.981 pp | 1.89% +1.894 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 8 | NAN FUNG GROUP HOLDINGS LTD | 514.7K +— (+0.0%) | 10.28M +1.2M (+13.6%) | 0.98% +0.000 pp | 9.20% -5.978 pp | USD9.20 +117.1% | 12 qtrs — |
| 9 | PERCEPTIVE ADVISORS LLC | 493.8K +493.8K (+100.0%) | 9.86M +9.9M (+100.0%) | 0.94% +0.938 pp | 0.18% +0.176 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 10 | ALYESKA INVESTMENT GROUP, L.P. | 331.3K +200.0K (+152.3%) | 6.62M +4.3M (+186.6%) | 0.63% +0.380 pp | 0.02% +0.012 pp | USD19.60 +1.9% | 4 qtrs — |
| 11 | WOODLINE PARTNERS LP | 201.2K +117.4K (+140.0%) | 4.02M +2.5M (+172.6%) | 0.38% +0.223 pp | 0.02% +0.009 pp | USD19.43 +2.8% | 3 qtrs — |
| 12 | SYQUANT CAPITAL SAS | 192.7K +192.7K (+100.0%) | 3.85M +3.8M (+100.0%) | 0.37% +0.366 pp | 0.47% +0.471 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 13 | FOLKETRYGDFONDET | 182.8K +182.8K (+100.0%) | 3.65M +3.7M (+100.0%) | 0.35% +0.347 pp | 0.09% +0.085 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 14 | PROPEL BIO MANAGEMENT, LLC | 172.8K +172.8K (+100.0%) | 3.45M +3.5M (+100.0%) | 0.33% +0.328 pp | 2.95% +2.947 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 15 | CITADEL ADVISORS LLC | 165.5K +165.5K (+100.0%) | 3.30M +3.3M (+100.0%) | 0.31% +0.314 pp | 0.00% +0.001 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 16 | NEO IVY CAPITAL MANAGEMENT | 54.8K +54.8K (+100.0%) | 2.55M +2.5M (+100.0%) | 0.10% +0.104 pp | 0.40% +0.402 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 17 | COMPAGNIE LOMBARD ODIER SCMA | 107.3K +10.3K (+10.6%) | 2.14M +423.0K (+24.6%) | 0.20% +0.020 pp | 0.02% +0.004 pp | USD10.74 +85.9% | 12 qtrs — |
| 18 | ACUTA CAPITAL PARTNERS, LLC | 101.8K +— (+0.0%) | 2.03M +243.2K (+13.6%) | 0.19% +0.000 pp | 1.38% -0.469 pp | USD19.03 +4.9% | 4 qtrs — |
| 19 | SIMPLIFY ASSET MANAGEMENT INC. | 98.8K +98.8K (+100.0%) | 1.97M +2.0M (+100.0%) | 0.19% +0.188 pp | 0.03% +0.032 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 20 | BANK OF AMERICA CORP /DE/ | 64.0K +25.4K (+66.0%) | 1.28M +599.7K (+88.5%) | 0.12% +0.048 pp | 0.00% +0.000 pp | USD17.01 +17.4% | 11 qtrs — |
| 21 | ALPS ADVISORS INC | 46.9K +46.9K (+100.0%) | 937.5K +937.5K (+100.0%) | 0.09% +0.089 pp | 0.01% +0.006 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 22 | UBS GROUP AG | 45.9K -28.8K (-38.6%) | 916.9K -396.8K (-30.2%) | 0.09% -0.055 pp | 0.00% 0.000 pp | USD16.61 +20.2% | 12 qtrs — |
| 23 | MARSHALL WACE, LLP | 45.8K +45.8K (+100.0%) | 914.1K +914.1K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.001 pp | USD19.97 +0.0% | 3 qtrs — |
| 24 | HRT FINANCIAL LP | 43.9K +43.9K (+100.0%) | 876.0K +876.0K (+100.0%) | 0.08% +0.083 pp | 0.00% +0.003 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 25 | GEODE CAPITAL MANAGEMENT, LLC | 36.1K +6.6K (+22.5%) | 720.1K +198.2K (+38.0%) | 0.07% +0.013 pp | 0.00% +0.000 pp | USD16.10 +24.0% | 8 qtrs — |
| 26 | RENAISSANCE TECHNOLOGIES LLC | 25.0K +25.0K (+100.0%) | 499.3K +499.3K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.001 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 27 | TWO SIGMA INVESTMENTS, LP | 24.4K +24.4K (+100.0%) | 488.1K +488.1K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.001 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 28 | NORTHERN TRUST CORP | 21.2K -615.0 (-2.8%) | 423.1K +39.8K (+10.4%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD15.18 +31.6% | 6 qtrs — |
| 29 | MILLENNIUM MANAGEMENT LLC | 15.6K +15.6K (+100.0%) | 312.4K +312.4K (+100.0%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 30 | GSA CAPITAL PARTNERS LLP | 13.0K +13.0K (+100.0%) | 260.0K +260.0K (+100.0%) | 0.02% +0.025 pp | 0.02% +0.022 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 31 | STATE STREET CORP | 12.5K +140.0 (+1.1%) | 250.0K +30.5K (+13.9%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD19.06 +4.8% | 4 qtrs — |
| 32 | BNP PARIBAS ARBITRAGE, SNC | 3.6K +3.6K (+100.0%) | 71.9K +71.9K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 33 | JPMORGAN CHASE & CO | 3.2K +3.2K (+100.0%) | 63.5K +63.5K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 34 | MORGAN STANLEY | 3.1K -3.4K (-52.5%) | 60.9K -51.9K (-46.0%) | 0.01% -0.006 pp | 0.00% +0.000 pp | USD19.25 +3.7% | 4 qtrs — |
| 35 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 2.0K +1.0K (+100.0%) | 39.9K +22.4K (+127.2%) | 0.00% +0.002 pp | 0.00% +0.002 pp | USD18.77 +6.4% | 2 qtrs — |
| 36 | JONES FINANCIAL COMPANIES LLLP | 210.00 +210.0 (+100.0%) | 4.2K +4.2K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.97 +0.0% | 1 qtrs NEW |
| 37 | DUPONT CAPITAL MANAGEMENT CORP | 4.00 +— (+0.0%) | 80.00 +9.0 (+12.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD7.25 +175.4% | 12 qtrs — |
| 38 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 20.00 +20.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.00 +5.1% | 1 qtrs NEW |
| 39 | SBI SECURITIES CO., LTD. | 1.00 +— (+0.0%) | 20.00 +2.0 (+11.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.00 +5.1% | 4 qtrs — |
| 40 | WOLVERINE ASSET MANAGEMENT LLC | — -269.0 (-100.0%) | — -4.7K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.76% | 435.5K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.40% | 850.9K | 0.50% |
| 3 | State Street SPDR S&P International Small Cap ETF GWX | 0.04% | 322.3K | 0.40% |
| 4 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.00% | 342.1K | 0.21% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
57.17M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gudrun Bachmann | Chief Technology Officer | — | female |
| Katie Kazem | Chief Legal Officer | — | female |
| Páll Ragnar Jóhannesson | Chief Business Officer | — | male |
| Ramin Tadayoni | Chief Scientific Officer | — | — |
| Rebecca Weil | Chief Commercial Officer | — | female |
| Riad Sherif | Chief Executive Officer & Director | — | — |
| Sharon Klier | Chief Development Officer | — | — |
| Snehal Shah | President of Research & Development | — | — |
| Sylvia Cheung | Chief Financial Officer | — | female |
| Virginia R. Dean | Chief Human Resources Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OCS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
